Best Grants for Cancer Nonprofits in American Samoa

The Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional) aims to enhance cancer treatment by integrating imaging and liquid biopsy assays. This initiative, led by the National Cancer Institute (NCI), encourages grant applications focused on assessing therapy responses and resistance emergence in patients. Key deadlines for submissions span from February 2025 to January 2028, providing ample opportunities for researchers to contribute to this vital area of cancer research.

The NCI Pathway to Independence Award (K99/R00) aims to support talented postdoctoral researchers in their transition to independent faculty positions. This program provides essential NCI research funding to help awardees establish competitive, independent research careers. Applications must be submitted by 5:00 PM local time of the applicant's organization, ensuring timely consideration for this critical funding opportunity.

The National Human Genome Research Institute (NHGRI) is launching a Notice of Funding Opportunity (NOFO) aimed at enhancing genomic research through the development and distribution of high-value resources. This initiative encourages collaborative efforts in genomic resource development and the integration of data science in clinical applications. While applications are not currently being accepted, prospective applicants are urged to prepare meaningful collaborations and projects ahead of the formal solicitation.

The Cancer Center Support Grants (CCSGs) aim to bolster NCI-Designated Cancer Centers through funding that supports diverse research activities. These grants enhance comprehensive, clinical, and basic cancer research while fostering collaboration among institutions. The program prioritizes interdisciplinary approaches to advance cancer prevention, diagnosis, and treatment, ultimately reducing cancer's impact on public health. CCSGs also facilitate resource sharing, administrative support, and the development of innovative research initiatives.

The National Cancer Institute (NCI) is inviting applications for the Specialized Programs of Research Excellence (SPOREs) in Human Cancers for 2027-2029. This funding opportunity supports innovative translational research aimed at improving prevention, detection, and treatment of organ-specific cancers. Eligible projects may address related cancer types from the same organ system or focus on common biological mechanisms. The program emphasizes research that translates findings into clinical applications, with the goal of achieving a human endpoint during the grant period.

The National Cancer Institute's PAIRS program aims to explore innovative cancer therapies by leveraging synthetic vulnerabilities that interact with tumor responses to radiation therapy. This initiative supports the development of targeted drug-radiation combinations, focusing on precision medicine to optimize treatment efficacy while minimizing harm to normal tissues. By consolidating prior funding opportunities, PAIRS encourages research that addresses context-dependent vulnerabilities, enhancing therapeutic strategies and aligning with NIH's scientific goals.

The Cancer Center Support Grants (CCSGs) aim to bolster NCI-Designated Cancer Centers by funding comprehensive, clinical, and basic cancer research. These grants facilitate the integration of diverse research capabilities, promoting innovative approaches to cancer prevention, diagnosis, and therapy. CCSGs encourage collaboration among researchers and the development of Shared Resources, ultimately enhancing the understanding of cancer and its treatment. This initiative supports the continuous discovery and dissemination of crucial research findings for community benefit.

The National Cancer Institute (NCI) invites research applications focused on early-onset cancers (ages 18-49), aiming to uncover their etiology and biological mechanisms. This funding opportunity supports studies that explore modifiable risk factors, biological responses, and improved identification of at-risk individuals. The initiative seeks to address the concerning rise in these cancers among young adults, facilitating essential prevention and control strategies. Applicants can choose between exploratory or research project formats, with project durations ranging from 2 to 5 years.

The National Cancer Institute's STRIPE program aims to advance cancer therapy by investigating the effects of radionuclide-emitted radiation. This initiative encourages multidisciplinary research to understand how radiation impacts normal tissues and tumor cells, ultimately improving therapeutic outcomes. By consolidating various funding mechanisms, STRIPE seeks to lower entry barriers for researchers, enhance the scientific foundation of radiopharmaceutical therapy, and foster innovative treatment strategies. Projects can be exploratory or research-focused, with flexible timelines for completion.

The Canine Cancer Immunotherapy Network (K9CIN) aims to advance canine cancer treatments through innovative clinical trials, paralleling the development of human therapies. This initiative is vital as pet dogs naturally develop cancer, mirroring human responses to treatments. By leveraging NIH support, K9CIN will facilitate research to enhance immunotherapeutic strategies for both dogs and humans, fostering a collaborative environment for veterinary and human medical advancements. Ultimately, this funding opportunity promotes ethical research that benefits both species.

This funding opportunity aims to bolster the cancer surveillance workforce through educational initiatives. By enhancing collaborations with cancer partners and developing tools for improved data quality, this program will expand the capacity of registrars. Efforts will focus on recruitment and retention, ultimately ensuring compliance with Public Law 102-515. Strengthening the cancer registrar workforce will lead to timely and accurate cancer data submission, supporting public health objectives.

The NCI Pathway to Independence Award (K99/R00) supports early-stage postdoctoral researchers transitioning to independent faculty positions. This funding opportunity encourages talented individuals with clinical or research doctoral degrees to lead independent clinical trials. Applicants should aim to foster research careers in cancer control, prevention, and data sciences. This initiative provides essential support during the transition from mentored positions to independent research roles, enhancing the pool of independent investigators in cancer research.

The NCI Pathway to Independence Award (K99/R00) supports early-stage postdoctoral researchers aiming to transition to independent faculty positions. It encourages candidates with doctoral degrees in research or clinical fields to apply, particularly those in cancer control and prevention. This funding opportunity facilitates a quick shift from mentored research to independent careers, providing essential support for awardees to establish competitive research programs without leading their own clinical trials.

The National Cancer Institute invites applications for the validation of biomarkers and assays for cancer detection and treatment. This funding opportunity supports both analytical and clinical validation of assays, emphasizing the importance of human samples. The program encourages multi-disciplinary collaboration and aims to enhance the performance and reproducibility of cancer assays across clinical laboratories. Applications are due by 5:00 PM local time during the designated deadlines each year.

The Exploratory Grant Award aims to enhance workforce diversity in basic cancer research by supporting junior and Early Stage Investigators from underrepresented groups in the biomedical and social sciences. This initiative provides essential funding to bridge the gap for researchers completing their training, ensuring they have the resources needed to develop larger grant applications. Applications are due by 5:00 PM local time of the applicant organization, emphasizing the importance of timely submissions.

The Cancer Research Education Grants Program (R25) aims to enhance research education in areas crucial to the NIH mission. This program supports innovative courses that develop skills in cancer research, covering topics such as prevention, diagnosis, and treatment. Grant applications are encouraged to be creative and state-of-the-art, addressing the needs of patients and their families. Key deadlines for applications span from January 2024 to September 2026, ensuring ongoing support for educational initiatives.

The Cancer Health Equity Research Centers (CHERCs) initiative by the American Cancer Society aims to address health disparities by supporting research focused on social determinants affecting cancer care. This program encourages innovative projects that engage communities, enhance access, and improve outcomes across diverse populations. By fostering collaborations and promoting multidisciplinary approaches, CHERCs strive to create equitable cancer prevention and treatment solutions, ensuring that all individuals have fair opportunities for cancer care and survivorship.

The Institutional Research Grants (IRG) program by the American Cancer Society provides essential seed funding for newly independent investigators to launch cancer research projects. Aimed at junior faculty, these grants offer $120,000 annually for three years, supporting the development of preliminary results necessary for competing for larger national grants. Eligible applicants must be at US academic institutions and hold the rank of Associate or Full Professor, with a proven track record in research and mentorship.

The American Cancer Society (ACS) and the American Society for Radiation Oncology (ASTRO) co-fund the Clinician Scientist Development Grant (CSDG), aimed at advancing the research careers of clinician scientists in radiation oncology. Eligible applicants are full-time faculty members at U.S. institutions with a doctoral degree and an active clinical license. The grant supports research for 3 to 5 years, providing $135,000 annually for direct costs, plus allowable indirect costs, while encouraging diversity in applications.

The DoW Rare Cancers Concept Award for FY26 promotes groundbreaking ideas in rare cancer research. This award encourages innovative applications that explore novel courses of investigation without requiring preliminary data. Unique to this program is the prohibition against mentioning the Principal Investigator or collaborators in the proposal materials, ensuring an unbiased review process. This funding opportunity aims to advance scientific discovery in the rare cancer domain.

This funding opportunity invites applications for R01 grants focused on molecular imaging methods to explore cancer inflammation in vivo. It aims to enhance understanding of dynamic interactions between inflammation and cancer through innovative imaging techniques. The initiative encourages collaborations between cancer researchers and imaging scientists to leverage molecular imaging for identifying cellular physiology changes in response to treatment. Deadline dates for applications range from February 2025 to October 2027, emphasizing timely submission for prospective researchers.

The Tobacco, Alcohol, and Cannabis Policy Research for Health Equity (R21 Clinical Trial Optional) aims to fund projects that explore policies related to tobacco, alcohol, and cannabis in the U.S. The focus is on understanding how these policies affect usage and exposure among disadvantaged populations. Engaging community organizations is essential for promoting equity in cancer prevention. This initiative is crucial for advancing health equity and reducing disparities in substance use.

The National Cancer Institute (NCI) invites applications for the validation of molecular, cellular, and imaging markers for cancer detection and treatment. This funding opportunity supports both analytical and clinical validation phases, emphasizing multi-disciplinary collaboration. The UH2 phase focuses on analytical validation, while the UH3 phase extends to clinical validation using well-annotated biospecimens. Proposals should justify the relevance of assays for clinical use and may include harmonization efforts across laboratories.

The National Cancer Institute (NCI) seeks to enhance the validation of biomarkers and assays for cancer detection and treatment through its UH3 funding mechanism. This initiative supports multi-disciplinary collaborations to validate existing assays over three years using clinical trial specimens. Emphasis is placed on harmonizing laboratory tests and validating pharmacodynamic markers. Projects should not focus on early-stage technology development but aim for integration into clinical studies as investigational assays.

The NIH is inviting applications for interventions aimed at enhancing cancer screening and preventive services in underserved populations. This initiative focuses on addressing barriers to healthcare access and promoting timely follow-up on abnormal findings. Collaborations with community partners are encouraged to foster effective outreach. The program particularly seeks to engage patients, clinicians, and healthcare settings in improving health equity and outcomes in cancer prevention.

The National Cancer Institute (NCI) invites applications for studies on mechanisms by which bariatric surgery influences cancer risk. This funding opportunity encourages exploration beyond short-term outcomes like weight loss and diabetes. The goal is to support innovative proof of concept studies, emphasizing feasibility without prior development in the literature. Unpublished data is not allowed, but references from preprints with a DOI are acceptable. Deadlines for applications span from February 2025 to November 2027.

The National Cancer Institute (NCI) is seeking applications for studies that explore how bariatric surgery influences cancer risk, emphasizing the need for innovative research in this area. This funding opportunity encourages the participation of researchers who focus on the long-term impacts of bariatric surgery beyond weight loss and diabetes, addressing critical gaps in understanding the disease mechanisms involved. Key deadlines for application submissions span from February 2025 to October 2027.